Key Drivers
- Strong cash-generation
- Solid returns
- Intangible concentration
AIAI Summary
Pediatrix's investment case has shifted from defensive undervalued healthcare to a cash‑flow‑centric neonatology consolidator—so value depends on sustained FCF and margin recovery (RCM, acuity, admin fees) rather than top‑line growth. Key action: monitor quarterly DSO/AR trends and margin trajectory closely (a reversal would rapidly erode buybacks/M&A optionality), while a consistent quarter‑over‑quarter DSO improvement and margin lift would materially re‑rate the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash-generation
- •Solid returns
- •Intangible concentration
MD delivers strong 2025 cash generation, solid returns and modest valuation but carries concentration in intangibles and softer Q4 margins that merit monitoring.
Price Behavior
Key Price Behavior Insights:
- •Neutral range
- •Rebounded modestly
- •Resistance capped
MD is trading neutral and range-bound over the last month around the $19.70 average, holding support near $19.3–$19.6 after a modest rebound from $18.82 but capped at resistance near $20.06–$20.10, so watch a breach of $19.3 for downside or a clean break above $20.10 for short-term bullish follow-through.
Narrow ~6–7% swing and low volatility after rebound from $18.82
Sentiment & News
Key News Insights:
- •Analyst bullishness
- •Institutional divergence
- •Neonatology focus
Pediatrix is receiving renewed bullish analyst coverage for stronger payer mix, higher neonatology acuity, selective M&A and apparent undervaluation, while institutional holdings remain mixed and the company reinforces clinical visibility with its annual NEO conference.
Continued positive fundamental narrative and M&A strategy should support valuation upside, though mixed institutional selling adds near-term uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings